Options for buying a cannabis business in a dry capital market. Other Noteworthy Updates It’s 2024 And federal Law Still Does Not Protect Medical Marijuana Users From Getting Fired For Testing Positive (Mondaq). Cannabis Tax Frenzy (Forbes). Medical marijuana companies have stronger 280E argument: Former U.S. Justice Department’s Tax Division Official’s Opinion. Navigating Hemp
In a study published in the journal Drug and Alcohol Dependence, researchers from Columbia University Mailman School of Public Health and other institutions examined the changes in cannabis use disorder (CUD) treatment associated with cannabis policy (Forbes). The legal landscape of flying with marijuana in the United States, from state vs. federal laws to TSA’s stance and potential
The cannabis industry is one of the most dynamic and complex sectors in the country, with varying degrees of legalization and regulation across different states and federal levels. Keeping track of federal cannabis-related bills and their status can be a daunting and time-consuming task. CannaSweep’s Congressional Bill Tracker is an outsourcing solution that industry members can
CannaSweep’s Congressional Bill Tracker Can Enhance Your Cannabis Business Read More »
Cornerstone Risk Solutions, a subsidiary of IMA Financial Group, today announced the launch of CLIC Risk Retention Group Inc. (CLIC RRG), to meet the needs of the cannabis industry. Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD Other Noteworthy Updates Dr. Aggarwal submitted federal appeal to challenge the
Q&A with Wine & Spirits Wholesalers of America’s (WSWA) President and CEO Francis Creighton – responding to a question about hemp-derived beverage brands on the show floor, he said “in a world where hemp and cannabis products are becoming more and more accepted, we have to roll with those market changes.” After relaxing its rules
Senate Banking Committee Chairman Sherrod Brown (D-OH) cited cannabis banking legislation as a way for bipartisan collaboration on his panel. Other Noteworthy Updates New research gains ground in detecting recent cannabis use with 96% accuracy for identifying recent cannabis smoking. An assessment of current CBD safety standards – The increasing popularity and availability of CBD products
Michigan Chamber Of Commerce Calls On Congress To Pass Marijuana Banking Bill (SAFER Banking Act), Citing Raft Of Retail Break-Ins. The following 2024 NCSL table includes states that have some kind of statutory or constitutional language requiring employers to not refuse employment or otherwise discriminate against a qualifying medical cannabis patient (or medical cannabis “cardholder” in
Gun groups not sold on cannabis banking bill – Both the National Rifle Association (NRA) and Gun Owners of America have concerns about the legislation Other Noteworthy Updates The American Society of Clinical Oncology posts a retrospective look at medical cannabis use at a cancer center Is CBD facing an existential crisis? Bethany Gomez, co-founder
As OFW Law’s Cannabis Team launches our new blog, CannaSweep, the team thought it would be helpful to explain what all is “swept” under the cannabis umbrella. For our first post, we describe what “cannabis” is and how it has found its way into agriculture, foods, cosmetics, drugs, and other commercial applications. It’s all Cannabis
Below we introduce OFW Law’s newest practice group focused on Cannabis. Tish Eggleston Pahl is a Principal at OFW Law. Ms. Pahl is highly experienced counsel to trade associations, and drug, cosmetic, dietary supplement, and food companies. She assists clients interested in manufacturing and marketing human and animal prescription and over-the-counter drugs, dietary supplements,
Meet the OFW Law Cannabis Team Read More »
As part of its ongoing enforcement against unlawful cannabis-containing foods and dietary supplements, the U.S. Food and Drug Administration (FDA) has recently posted two new Warning Letters against cannabis marketers:
CBD and Delta-8 THC: FDA Enforcement Update Read More »
On October 25, 2023, USDA’s Agriculture Marketing Service (AMS) Secretary Vilsack previewed the Organic Livestock and Poultry Standards (OLPS) Final Rule. The Final Rule will amend the National Organic Program (NOP) regulations by adding new provisions for livestock handling and transport for slaughter and avian living conditions. The Final Rule will also expand existing requirements
October Food and Agriculture Regulatory Recap Read More »
On August 18, 2023, comments were due to Congress on the bipartisan and bicameral request for information (RFI), which sought written stakeholder comments and analysis to “asses[s] the potential for a regulatory pathway for hemp-derived [cannabidiol (CBD)] products that prioritizes consumer safety and provides certainty to the U.S. market.” By way of background on July
On July 5, 2023, FDA and the Federal Trade Commission (FTC) jointly sent six (6) cease and desist letters to companies marketing and selling edible products containing Delta-8 tetrahydrocannabinol (THC) in packaging similar to snacks and candy ordinarily eaten by children On July 27, 2023, the House Oversight and Accountability Subcommittee on Health Care and
July Food and Agriculture Regulatory Recap Read More »
On Friday, U.S. Food and Drug Administration (FDA) released its first draft guidance on the conduct of clinical trials for psychedelic drugs. The Draft Guidance for Industry, Psychedelic Drugs: Considerations for Clinical Investigations, if finalized, will guide researchers investigating psychedelics as potential treatments for medical conditions. There has been significant media, marketing, and legislative interest
FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs Read More »
The United States Department of Agriculture (USDA) will include ‘Hemp’ in the title of one of the six Agricultural Technical Advisory Committees (ATACs) – noting a significant evolution in both agriculture and cannabis policy. Specifically, ‘Hemp’ has now earned a place within the ATAC titled ‘Tobacco, Cotton, Peanuts, and Hemp.’ The ATACs were established under
Hemp Now Included in Agricultural Technical Advisory Committee (ATAC) Read More »
Earlier this year, the U.S. Food and Drug Administration (FDA) concluded that existing regulatory frameworks for food and supplements are not appropriate for cannabidiol” (CBD) and the agency will “work with Congress on a new way forward.” Since this announcement, speculation on how FDA and Congress will work to handle the ever-evolving over $9.1 billion
Cannabis Regulatory Update: CBD, The Farm Bill, and The Punt from FDA to Congress Read More »
On March 17, 2023, FSIS announced it will make “Temporary Allowance for Use of Sodium Nitrite from Natural Sources, ”as a way to handle shortages of synthetic sodium nitrite used to cure meat and poultry products. Establishments interested in using the substitution may submit for temporary label approval under 9 C.F.R. § 412(1)(f). On March
March Food and Agriculture Regulatory Recap Read More »
2022 Achievements – On February 6, 2023, FSIS posted a list of the key achievements in 2022. These include the Agency’s efforts to reduce illnesses linked to Salmonella in poultry, support small and very small establishments, the result of the “Product of the USA” labeling survey, state inspection programs, collaboration, and fostering diversity, equity, and
February Food and Agriculture Regulatory Recap Read More »
On January 4, 2023, the Office of Management and Budget (OMB) released the Semiannual Regulatory Agendas for Fall 2022. All Federal Agency Regulatory Agendas can be found here. On December 20, 2023, the U.S. Federal Trade Commission (FTC) published a regulatory review; request for public comment on “Guides for the Use of Environmental Marketing Claims
January Food and Agriculture Regulatory Recap Read More »
The building 2023 Farm Bill pressures coincide with FDA signaling that it will soon be taking significant action on cannabinoids. In addition to the November 2022 warning letters: In December 2022, FDA Chief Scientist Dr. Namandjé N. Bumpus said that “CBD science” is a top priority and that there are broad cross-agency initiatives underway, and
December Food and Agriculture Regulatory Recap Read More »
Today, December 2, 2022, President Biden signed into law H. R. 8454 to expand research on cannabidiol and marijuana, and for other purposes which will create cannabis research opportunities for medical cannabis and will protect doctors who advise their patients about medical cannabis. The bill was passed unanimously in both the House and the Senate
Federal Cannabis Research Bill Signed into Law Read More »
On November 1, 2022, the Principal Deputy Commissioner of the U.S. Food and Drug Administration (FDA) Janet Woodcock had a virtual meeting on “Regulatory Pathways for Hemp Products, including Cannabidiol (CBD)” with representatives of the U.S. Health and Human Services Office of the Secretary and the Executive Office of the President. This meeting was announced
FDA’s Woodcock Holds Meeting on Regulatory Pathways for Hemp and CBD Read More »
In October, the United States Securities and Exchange Commission (SEC) announced that it would be charging two (2) cannabis companies, Emerald Health and HighTimes, and six (6) associated individuals who worked with the companies, for their involvement in “stock promotion schemes.” Stock promotion schemes are “fraudulent schemes to promote the securities of issuers that were conducting
SEC Stock Promotion Scheme Charges Against the Cannabis Industry Read More »
At the end of September, the United States Food and Drug Administration (FDA) hired cannabis policy expert Norman Birenbaum as a Senior Public Health Advisor at FDA’s Center for Regulatory Programs. Mr. Birenbaum comes to FDA with a deep background in regulation in several state cannabis departments. Most recently, in New York State he served
On July 26, 2022, the Senate Judiciary Committee’s Subcommittee on Criminal Justice and Terrorism held a hearing on “Decriminalizing Cannabis at the Federal Level: Necessary Steps to Address Past Harms.” The hearing largely addressed the recently introduced S. 4591, “Cannabis Administration and Opportunity Act” (the “CAOA”). The witnesses included: Malik Burnett, Medical Director, Maryland Department
On Thursday, July 21, 2022, Senators Chuck Schumer (D-NY) Cory Booker (D-NJ), and more officially filed the Cannabis Administration and Opportunity Act (CAOA) (S.4591) to legalize cannabis nationwide. OFW has prepared material on this bill and will be monitoring supplementary announcements and hearings for more information. Please note that OFW has provided other posts on key areas of interest in
CAOA Filed in the Senate Read More »
On May 4, 2022, the United States Food and Drug Administration (FDA) issued for the first time Warning Letters to companies selling products containing delta-8 tetrahydrocannabinol (delta-8 THC). While the FDA has sent warnings to companies utilizing hemp-derived cannabidiol (CBD) before, this is the first set of Warning Letters to those selling delta-8 THC products for
FDA Issues First Set of Warning Letters to Companies Selling Delta-8 THC Read More »
Background By the end of 2021, ninety-one percent of Americans reported favoring some form of marijuana legalization. To date, eighteen (18) states and Washington, DC, have legalized adult recreational use of marijuana, and thirty-seven (37) states and four (4) territories have medical use programs. More states will likely be expanding access to marijuana with ballot
